A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors

NCT06598007 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: CT3001

Sponsor

Crossignal Therapeutics, Inc.